Full text is available at the source.
Abstract
Among 120 patients with inflammatory bowel disease, gastrointestinal side effects were reported in 11.5% of those treated with glucagon-like peptide receptor agonists.
- Semaglutide was associated with significant weight reduction in patients.
- C-reactive protein levels decreased after one year of treatment.
- No differences were found in IBD-related hospitalizations or endoscopic scores.
Simplified